title: Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.
abstract: OBJECTIVE
  To assess the safety and efficacy of carvedilol when administered to heart failure patients already receiving amiodarone.
  
  
  METHODS
  Retrospective analysis of the clinical outcome of 230 patients treated with carvedilol for chronic heart failure, stratified according to whether they were already receiving amiodarone (amiodarone group, 80 patients) or not (non-amiodarone group, 130 patients) at baseline.
  
  
  METHODS
  Heart failure clinic at a university affiliated public teaching hospital.
  
  
  METHODS
  Incidence of adverse events; changes in functional status and echocardiographic dimensions at three months.
  
  
  RESULTS
  Adverse reactions to carvedilol occurred in 33 (41%) of the amiodarone group and 43 (29%) of the non-amiodarone group (p = 0.049). Carvedilol was discontinued in 21 (26%) of the amiodarone group and 37 (25%) of the non-amiodarone group (NS). The clinical outcome at three months did not differ significantly between the two groups; 31 (39%) of the amiodarone group improved their New York Heart Association status, 28 (35%) were unchanged, and 21 (26%) deteriorated compared with 67 (45%), 51 (34%), and 32 (21%), respectively, for the non-amiodarone group (NS). Both groups had highly significant decreases in heart rate and left ventricular end systolic dimension, and a significant increase in left ventricular ejection fraction after three months of carvedilol treatment, with no significant differences between the groups.
  
  
  CONCLUSIONS
  The beneficial effects of carvedilol on left ventricular remodelling, systolic function, and symptomatic status are not affected by concurrent treatment with amiodarone. Adverse reactions necessitating cessation of carvedilol are no more frequent in patients receiving amiodarone.
authors.affiliation: Heart Failure and Transplant Unit, St Vincent's Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia. pmacdonald@stvincents.com.au
authors.forename: P S
authors.initials: PS
authors.lastname: Macdonald
authors.forename: A M
authors.initials: AM
authors.lastname: Keogh
authors.forename: C
authors.initials: C
authors.lastname: Aboyoun
authors.forename: M
authors.initials: M
authors.lastname: Lund
authors.forename: R
authors.initials: R
authors.lastname: Amor
authors.forename: D
authors.initials: D
authors.lastname: McCaffrey
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077261:Carvedilol; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D020257:Ventricular Remodeling / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D000638:Amiodarone